Coya Non Current Liabilities Total from 2010 to 2024
| COYA Stock | 6.12 0.11 1.77% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 574.7 K | Current Value 546 K | Quarterly Volatility 3.2 M |
Check Coya Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coya Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.4 K, Interest Expense of 2.9 M or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 10.04, Dividend Yield of 0.0 or PTB Ratio of 3.84. Coya financial statements analysis is a perfect complement when working with Coya Therapeutics, Valuation or Volatility modules.
Coya | Non Current Liabilities Total |
Latest Coya Therapeutics,'s Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Coya Therapeutics, Common over the last few years. It is Coya Therapeutics,'s Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coya Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Coya Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 1,324,134 | |
| Geometric Mean | 602,311 | |
| Coefficient Of Variation | 243.35 | |
| Mean Deviation | 1,552,179 | |
| Median | 447,121 | |
| Standard Deviation | 3,222,317 | |
| Sample Variance | 10.4T | |
| Range | 12.5M | |
| R-Value | 0.33 | |
| Mean Square Error | 10T | |
| R-Squared | 0.11 | |
| Significance | 0.24 | |
| Slope | 234,610 | |
| Total Sum of Squares | 145.4T |
Coya Non Current Liabilities Total History
About Coya Therapeutics, Financial Statements
Coya Therapeutics, stakeholders use historical fundamental indicators, such as Coya Therapeutics,'s Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Coya Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Coya Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Coya Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Coya Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 574.7 K | 546 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out the analysis of Coya Therapeutics, Correlation against competitors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.